 - Participants enrolled in the multicenter, randomized, double-blind, parallel-group, placebo-controlled, variable treatment duration study comparing the efficacy and safety of BAF312 to placebo in patients with Secondary Progressive Multiple Sclerosis SPMS Protocol No. CBAF312A2304 sponsored by Novartis. Refer to ClinicalTrials.gov record NCT01665144. 